653 related articles for article (PubMed ID: 29162480)
1. Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells.
Kim JS; Shin DH; Kim JS
J Control Release; 2018 Jan; 269():245-257. PubMed ID: 29162480
[TBL] [Abstract][Full Text] [Related]
2. Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells.
Noh H; Zhao Q; Yan J; Kong LY; Gabrusiewicz K; Hong S; Xia X; Heimberger AB; Li S
Cancer Lett; 2018 Oct; 433():176-185. PubMed ID: 29991446
[TBL] [Abstract][Full Text] [Related]
3. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
[TBL] [Abstract][Full Text] [Related]
4. Brain Targeting by Liposome-Biomolecular Corona Boosts Anticancer Efficacy of Temozolomide in Glioblastoma Cells.
Arcella A; Palchetti S; Digiacomo L; Pozzi D; Capriotti AL; Frati L; Oliva MA; Tsaouli G; Rota R; Screpanti I; Mahmoudi M; Caracciolo G
ACS Chem Neurosci; 2018 Dec; 9(12):3166-3174. PubMed ID: 30015470
[TBL] [Abstract][Full Text] [Related]
5. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S
Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235
[TBL] [Abstract][Full Text] [Related]
6. Development of CD133 Targeting Multi-Drug Polymer Micellar Nanoparticles for Glioblastoma - In Vitro Evaluation in Glioblastoma Stem Cells.
Smiley SB; Yun Y; Ayyagari P; Shannon HE; Pollok KE; Vannier MW; Das SK; Veronesi MC
Pharm Res; 2021 Jun; 38(6):1067-1079. PubMed ID: 34100216
[TBL] [Abstract][Full Text] [Related]
7. Membrane-Decorated Exosomes for Combination Drug Delivery and Improved Glioma Therapy.
Liang S; Xu H; Ye BC
Langmuir; 2022 Jan; 38(1):299-308. PubMed ID: 34936368
[TBL] [Abstract][Full Text] [Related]
8. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
9. Cardamonin induces apoptosis by suppressing STAT3 signaling pathway in glioblastoma stem cells.
Wu N; Liu J; Zhao X; Yan Z; Jiang B; Wang L; Cao S; Shi D; Lin X
Tumour Biol; 2015 Dec; 36(12):9667-76. PubMed ID: 26150336
[TBL] [Abstract][Full Text] [Related]
10. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH
Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181
[TBL] [Abstract][Full Text] [Related]
11. Self-assembled angiopep-2 modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles delivery TMZ for glioma synergistic TMZ and RT therapy.
Zong Z; Hua L; Wang Z; Xu H; Ye C; Pan B; Zhao Z; Zhang L; Lu J; Mei LH; Rutong Y
Drug Deliv; 2019 Dec; 26(1):34-44. PubMed ID: 30744436
[TBL] [Abstract][Full Text] [Related]
12. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
[TBL] [Abstract][Full Text] [Related]
13. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
Yu Z; Zhao G; Xie G; Zhao L; Chen Y; Yu H; Zhang Z; Li C; Li Y
Oncotarget; 2015 Oct; 6(32):32930-43. PubMed ID: 26431379
[TBL] [Abstract][Full Text] [Related]
14. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
Verreault M; Wehbe M; Strutt D; Masin D; Anantha M; Walker D; Chu F; Backstrom I; Kalra J; Waterhouse D; Yapp DT; Bally MB
J Control Release; 2015 Dec; 220(Pt A):348-357. PubMed ID: 26528901
[TBL] [Abstract][Full Text] [Related]
15. Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization.
Garnier D; Meehan B; Kislinger T; Daniel P; Sinha A; Abdulkarim B; Nakano I; Rak J
Neuro Oncol; 2018 Jan; 20(2):236-248. PubMed ID: 29016925
[TBL] [Abstract][Full Text] [Related]
16. Synergistic inhibition of tumor growth by combination treatment with drugs against different subpopulations of glioblastoma cells.
Chang CH; Liu WT; Hung HC; Gean CY; Tsai HM; Su CL; Gean PW
BMC Cancer; 2017 Dec; 17(1):905. PubMed ID: 29284440
[TBL] [Abstract][Full Text] [Related]
17. Extracellular vesicles derived from hypoxic glioma stem-like cells confer temozolomide resistance on glioblastoma by delivering miR-30b-3p.
Yin J; Ge X; Shi Z; Yu C; Lu C; Wei Y; Zeng A; Wang X; Yan W; Zhang J; You Y
Theranostics; 2021; 11(4):1763-1779. PubMed ID: 33408780
[No Abstract] [Full Text] [Related]
18. Glioblastoma stem cells resistant to temozolomide-induced autophagy.
Fu J; Liu ZG; Liu XM; Chen FR; Shi HL; Pangjesse CS; Ng HK; Chen ZP
Chin Med J (Engl); 2009 Jun; 122(11):1255-9. PubMed ID: 19567133
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells.
Zhao K; Schäfer A; Zhang Z; Elsässer K; Culmsee C; Zhong L; Pagenstecher A; Nimsky C; Bartsch JW
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008590
[TBL] [Abstract][Full Text] [Related]
20. Glioblastoma stem cells deliver ABCB4 transcribed by ATF3 via exosomes conferring glioblastoma resistance to temozolomide.
Xu X; Zheng Y; Luo L; You Z; Chen H; Wang J; Zhang F; Liu Y; Ke Y
Cell Death Dis; 2024 May; 15(5):318. PubMed ID: 38710703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]